Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. by Yimin Hua, Timothy A Vickers, Brenda F Baker, C Frank Bennett, Adrian R Krainer

Get full text

Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events by Wesley Partridge, Sebastien A. Burel, Annie Ferng, Shuting Xia, T. Jesse Kwoh, Scott P. Henry, Brenda F. Baker

Get full text

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans by Nicholas R Jones, Melissa A Pegues, Mark A McCrory, Walter Singleton, Claudette Bethune, Brenda F Baker, Daniel A Norris, Rosanne M Crooke, Mark J Graham, Alexander J Szalai

Get full text

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data by Nicholas J. Viney, Shuling Guo, Li‐Jung Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien Burel, Sue Murray, Gustavo Buchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia

Get full text